Difference between revisions of "MSK Biomarker Ctte"

From QIBA Wiki
Jump to: navigation, search
(Meetings)
(Meetings)
Line 9: Line 9:
  
 
'''Approved call summaries:'''
 
'''Approved call summaries:'''
 +
*[[Media:2021_07-27_QIBA_MSK_BC_Call_Summary-FINAL.pdf|July 27, 2021]]
 
*[[Media:2021_04-27_QIBA_MSK_BC_Call_Summary-FINAL.pdf|April 27, 2021]]
 
*[[Media:2021_04-27_QIBA_MSK_BC_Call_Summary-FINAL.pdf|April 27, 2021]]
 
*[[Media:2021_03-23_QIBA_MSK_BC_Call_Summary-FINAL.pdf|March 23, 2021]]
 
*[[Media:2021_03-23_QIBA_MSK_BC_Call_Summary-FINAL.pdf|March 23, 2021]]
*[[Media:2021_02-23_QIBA_MSK_BC_Call_Summary-FINAL.pdf|February 23, 2021]]
 
  
 
'''''[[MSK Biomarker Committee Call Summaries Archive]]'''''
 
'''''[[MSK Biomarker Committee Call Summaries Archive]]'''''

Revision as of 16:13, 24 August 2021

Co-chairs: Xiaojuan Li, PhD; Thomas M. Link, MD, PhD
RSNA Staff Support: Susan Stanfa

The MSK Biomarker Committee seeks to develop a quantitative Profile for MSK.

Meetings

Approved call summaries:

MSK Biomarker Committee Call Summaries Archive

Working Documents

  • QIBA MSK Profile 2020-01-28: MR-based cartilage compositional biomarkers (T1ρ, T2) for risk prediction, early diagnosis and monitoring of treatment of degenerative joint disease

Statistical Reference Documents

Workflow Documents

Reference Materials